• They're like Medtronic or Baxter, but exclusively for MRI-compatible medical devices.
• Think of them as the Philips Healthcare of MRI-safe patient monitoring and IV infusion systems.

• MRidium MRI Compatible IV Infusion Pump System: An intravenous infusion pump system designed to function safely and accurately within the magnetic environment of an MRI scanner.
• MRI Compatible Patient Vital Signs Monitoring System: A system used to monitor critical patient vital signs safely and effectively during MRI procedures.
• Non-Magnetic IV Poles: Intravenous poles constructed from non-magnetic materials to ensure safety and compatibility within MRI environments.
• Wireless Remote Displays/Controls: Components that allow for remote operation and monitoring of medical devices used in MRI settings.
• Side Car Pump Modules: Additional pump modules that can be integrated with existing infusion systems to expand functionality.
• Dose Error Reduction Systems: Technologies implemented to minimize medication errors during intravenous drug administration in medical settings.
• SpO2 Monitoring with Sensors and Accessories: Devices and components for monitoring blood oxygen saturation levels, compatible for use in MRI environments.

Roger Susi
FOUNDER, PRESIDENT, AND CEO

Mr. Susi is the founder of iRadimed and has served as a member of the Board since the company's inception. He also founded, served as Chairman, and Chief Executive Officer of Invivo Research Inc., a medical device company and the predecessor to Invivo Corporation, which pioneered MRI-safe patient monitoring. Mr. Susi has over 40 years of management experience in the medical device industry. He resumed his duties as Chief Executive Officer and President of iRadimed in May 2020, having previously held these roles from the company's incorporation until August 2019.

John "Jack" Glenn
CHIEF FINANCIAL OFFICER

Mr. Glenn has served as Chief Financial Officer of iRadimed since 2022. He is a financial executive with over 30 years of experience directing corporate finance activities for both public and private companies. Prior to joining iRadimed, Mr. Glenn served as Chief Financial Officer at Esko Bionics. His extensive experience also includes CFO roles at Sonendo, Armetheon, Solta Medical, Cholestech, and Invivo Corporation. Notably, he assisted Solta Medical in its strategic acquisition by Valeant Pharmaceutical, and was involved when Cholestech was acquired by Alere Medical, and Invivo Corporation was sold to Intermagnetics General Corporation.

Jeffery Chiprin
CHIEF COMMERCIAL OFFICER

Mr. Chiprin has served as iRadimed's Chief Commercial Officer since November 2024, bringing over 30 years of senior leadership experience in medical technology from both private and public sectors. He was previously with Invivo Corporation, joining in 1996 and serving as Vice President of North American Sales for six years. He was part of the leadership team that facilitated the sale of Invivo Corporation to Philips Corporation. Following this, he spent 14 years as Vice President of Sales at Philips Corporation, and later served as Sr. Vice President of Worldwide Sales in private companies specializing in innovative MRI solutions.

Chris Williamson
EXECUTIVE VICE PRESIDENT OF CONTINUOUS IMPROVEMENT AND INFORMATION TECHNOLOGY

Mr. Williamson serves as the Executive Vice President of Continuous Improvement and Information Technology, where he is responsible for leading transformation initiatives aimed at supporting growth, maximizing operational efficiency, and enhancing profitability. He possesses over 20 years of experience in technology, business transformation, and operations within highly regulated industries.

iRadimed Corporation (IRMD) faces several key risks inherent to its specialized niche in MRI-compatible medical devices. These risks primarily stem from its concentrated product portfolio, the demanding regulatory environment, and vulnerabilities within its supply chain.

Key Risks to the Business:

1. Dependence on a Limited Product Range: iRadimed's financial performance is significantly reliant on a few core products, mainly its MRidium MRI compatible IV infusion pump systems and the 3880 MRI compatible patient vital signs monitoring system. This product concentration makes the company susceptible to market shifts, technological advancements, or any disruptions affecting these specific offerings, which could render them less competitive.
2. Regulatory Challenges and FDA Scrutiny: As a manufacturer of medical devices, iRadimed operates within a stringent regulatory landscape governed by the FDA and other international bodies. Increased scrutiny on 510(k) clearances, slower approval times for new devices, changes in regulations, or issues of non-compliance could lead to costly penalties, product recalls, operational restrictions, or delays in launching new products. The company has previously received an FDA warning letter related to software updates requiring new 510(k) submissions.
3. Supply Chain Vulnerabilities: iRadimed's reliance on third-party and, in some cases, single-source suppliers for critical components exposes it to potential supply chain disruptions. Such disruptions could result in manufacturing delays or interruptions, impacting the company's ability to meet customer demand and fulfill sales agreements. Global trade tensions also present a risk to the stability of its supply chain and overall input costs.

iRadimed (IRMD) operates in two primary addressable markets: MRI-compatible intravenous (IV) infusion pump systems and MRI-compatible patient vital signs monitoring systems.

MRI Compatible IV Infusion Pump Systems

The global market for MRI-compatible IV infusion pump systems was valued at approximately USD 381.16 million in 2025. This market is projected to grow to approximately USD 614.98 million by 2031, exhibiting a compound annual growth rate (CAGR) of 8.30% during this period. North America is a leading region in this market, holding a 44.10% share in 2025.

MRI Compatible Patient Vital Signs Monitoring Systems

The global MRI-compatible patient monitoring systems market is projected to be valued at approximately USD 4.3 billion in 2025. This market is expected to reach approximately USD 6.4 billion by 2035, growing at a CAGR of 4.0%. Another estimate places the global MRI monitoring devices market size at US$4.2 billion in 2025, anticipated to reach US$5.6 billion by 2032 with a CAGR of 4.2%. North America is identified as the largest market for MRI-compatible patient monitoring systems.

iRadimed (IRMD) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market dynamics:

1. Launch and Replacement Cycle of the New 3870 MRI-Compatible IV Infusion Pump System: The company anticipates a significant increase in revenue from the introduction and widespread adoption of its next-generation 3870 MRI-compatible IV infusion pump. This new pump, with enhanced usability and technology, is expected to catalyze a major replacement cycle for existing legacy pump systems among hospitals and imaging centers, as well as attract new customers. Management is targeting a $100 million-plus annual revenue run rate in 2026, with initial shipments commencing in late 2025 and a full general sales release in April 2026, leading to significant revenue contributions in the second half of 2026.
2. Growth in Patient Vital Signs Monitoring Systems and Disposables: The existing patient vital signs monitoring systems and associated disposable products are expected to continue contributing to revenue growth. The company has observed consistent gains in these product lines, with disposable revenue increasing due to higher utilization of its devices.
3. International Market Expansion: iRadimed plans to expand its market presence geographically, specifically targeting Europe by the end of 2026 and Japan by the summer of 2027. This expansion into new international markets is anticipated to broaden the company's reach for its MRI-compatible infusion systems and monitoring products.
4. Sustained Demand and Backlog for Legacy 3860 Pumps: Even with the introduction of the new 3870 pump, the legacy 3860 MRI-compatible infusion pump systems continue to experience strong demand. The company expects to maintain quarterly revenue in the first half of 2026, partly driven by the existing backlog of 3860 pumps.
5. Higher Average Selling Price (ASP) of the 3870 Pump: The new 3870 pump is expected to command a higher average selling price compared to its predecessor. This increased pricing power for the advanced product is anticipated to directly contribute to augmented revenue.

Share Repurchases

• iRadimed reported net share repurchases of $2.6 million in 2025.

Share Issuance

• No significant share issuances were reported in the last 3-5 years; the net figure for common shares in 2025 reflected a repurchase.

Outbound Investments

• iRadimed has not completed any acquisitions in the last few years, though it evaluates such opportunities.

Capital Expenditures

• Capital expenditures for the fiscal year 2025 were approximately $7.0 million and $8.2 million in 2024, primarily related to the construction of a new corporate office building which was completed in 2025.
• In November 2022, the company acquired approximately 27 acres of land in Orlando, Florida, for $7.3 million, related to its new facility.